Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings.

The Hippo pathway regulates organ size and tissue homeostasis by controlling cell proliferation and apoptosis. The YAP-TEAD transcription factor, the downstream effector of the Hippo pathway, regulates the expression of genes such as CTGF, Cyr61, Axl and NF2. Aberrant Hippo activity has been identified in multiple types of cancers. Flufenamic acid (FA) was reported to bind in a liphophilic TEAD palmitic acid (PA) pocket, leading to reduction of the expression of Axl and NF2. Here, we show that replacement of the trifluoromethyl moiety in FA by aromatic groups, directly connected to the scaffold or separated by a linker, leads to compounds with better affinity to TEAD. Co-crystallization studies show that these compounds bind similarly to FA, but deeper within the PA pocket. Our studies identified LM-41 and AF-2112 as two TEAD binders that strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 gave the strongest reduction of migration of human MDA-MB-231 breast cancer cells.

• Publication year

  2023

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2023-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2023.129488PMID 37770003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

  2023cited by this paper
• Therapeutic targeting of TEAD transcription factors in cancer.

  2023cited by this paper
• Abstract LB319: IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations

  2023cited by this paper
• The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition

  2022cited by this paper
• Small-Molecule Cyanamide Pan-TEAD·YAP1 Covalent Antagonists.

  2022cited by this paper
• Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells

  2022cited by this paper
• A chemical perspective on the modulation of TEAD transcriptional activities: Recent progress, challenges, and opportunities.

  2022cited by this paper
• Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)

  2022cited by this paper
• Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106.

  2022cited by this paper
• Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode

  2022cited by this paper
• Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling

  2022cited by this paper
• Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3

  2021cited by this paper
• Development of LM98, a Small‐Molecule TEAD Inhibitor Derived from Flufenamic Acid

  2021cited by this paper
• Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine

  2021cited by this paper
• Discovery of Covalent Inhibitors Targeting the Transcriptional Enhanced Associate Domain Central Pocket

  2020cited by this paper
• The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.

  2020cited by this paper
• Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

  2020cited by this paper
• Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling.

  2020cited by this paper
• Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.

  2019cited by this paper
• Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities.

  2019cited by this paper
• Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction.

  2019cited by this paper
• Antiproliferative and Antimigratory Effects of a Novel YAP–TEAD Interaction Inhibitor Identified Using in Silico Molecular Docking

  2019cited by this paper
• The Hippo Pathway: Biology and Pathophysiology.

  2019cited by this paper
• Identification of Quinolinols as Activators of TEAD-dependent Transcription.

  2019cited by this paper
• Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors.

  2019cited by this paper
• Discovery of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo signaling pathway inhibitors.

  2019cited by this paper
• Regulation of TEAD Transcription Factors in Cancer Biology

  2019cited by this paper
• Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine

  2018cited by this paper
• Regulation of the Hippo pathway in cancer biology

  2018cited by this paper
• The history and regulatory mechanism of the Hippo pathway

  2018cited by this paper
• Toward the Discovery of a Novel Class of YAP–TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP–TEAD Protein–Protein Interface

  2018cited by this paper
• The Hippo pathway in normal development and cancer

  2018cited by this paper
• Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.

  2018cited by this paper
• Hippo pathway - brief overview of its relevance in cancer.

  2017cited by this paper
• Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches

  2017cited by this paper
• Targeting Transcriptional Enhanced Associate Domains (TEADs).

  2017cited by this paper
• Structural Insights into the Regulation of Hippo Signaling.

  2017cited by this paper
• The Hippo pathway in organ development, homeostasis, and regeneration.

  2017cited by this paper
• YAP/TAZ at the Roots of Cancer.

  2016cited by this paper
• Autopalmitoylation of TEAD Proteins Regulates Transcriptional Output of Hippo Pathway

  2016cited by this paper
• Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.

  2016cited by this paper
• The roles of the Hippo pathway in cancer metastasis.

  2016cited by this paper
• Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy.

  2015cited by this paper
• Targeting Hippo pathway by specific interruption of YAP‐TEAD interaction using cyclic YAP‐like peptides

  2015cited by this paper
• The emerging roles of YAP and TAZ in cancer

  2015cited by this paper
• Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

  2015cited by this paper
• The biology of YAP/TAZ: hippo signaling and beyond.

  2014cited by this paper
• YAP and TAZ regulate skin wound healing.

  2014cited by this paper
• Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction.

  2014cited by this paper
• The Hippo pathway and human cancer

  2013cited by this paper
• The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment

  2013cited by this paper
• Emerging roles of TEAD transcription factors and its coactivators in cancers

  2013cited by this paper
• Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

  2012cited by this paper
• Hippo signaling: growth control and beyond

  2011cited by this paper
• The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal

  2011cited by this paper
• The hippo signaling pathway in development and cancer.

  2010cited by this paper
• Structural insights into the YAP and TEAD complex.

  2010cited by this paper
• Structural basis of YAP recognition by TEAD4 in the hippo pathway.

  2010cited by this paper
• Hippo signaling in organ size control.

  2007cited by this paper
• Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination

  2006cited by this paper

• Targeting YAP/TAZ-TEAD and their protein-protein interaction for precision cancer therapy.

  2025cites this paper
• TEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway

  2025cites this paper
• Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)

  2025cites this paper
• Advancements of anticancer agents by targeting the Hippo signalling pathway: biological activity, selectivity, docking analysis, and structure–activity relationship

  2024cites this paper
• A Role for the Hippo/YAP1 Pathway in the Regulation of In Vitro Vasculogenic Mimicry in Glioblastoma Cells

  2024cites this paper
• Transcriptional regulation of CYR61 and CTGF by LM98: a synthetic YAP-TEAD inhibitor that targets in-vitro vasculogenic mimicry in glioblastoma cells

  2024influential citation
• Strategies that regulate Hippo signaling pathway for novel anticancer therapeutics.

  2024cites this paper
• Development of HC-258, a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration.

  2023cites this paper